• Drug: bosentan
  • Manufacturer: misc
  • Route of Administration: Oral
  • Site of Care: Outpatient

  • Approved Indication:

    • treatment of pulmonary arterial hypertension (WHO group 1) in adults to improve exercise ability and to decrease clinical worsening
    • treatment of pulmonary arterial hypertension (WHO group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance which is expected to result in an improvement in exercise ability

  • Disease: pulmonary arterial hypertension

  • Therapeutic Area: Pulmonary

  • Enrollment Form Link: www.bosentanREMSprogram.com
  • Phone Number: 1-866-359-2612
  • Fax Number: 1-800-730-8231
  • Product Website: www.tracleer.com